Laura Sepp-Lorenzino

Thank you to all our members who voted in the recent election! We are pleased to announce the new OTS BOD for the 2026-2027 term. 2026-2027 OTS Board of Directors Learn more about our new BOD at oligotherapeutics.org/the-society/bo… #ots #oligotherapeutics #oligonucleotidetherapeutics

We’re proud to welcome Dr. Laura Sepp-Lorenzino to AskBio’s Board of Directors! With 30+ years of leadership in biotech, her insights will be key as we advance our clinical and pre-clinical #GeneTherapy candidates. Learn more: bit.ly/4crLjQj #AskBio #Leadership

$NTLA announces its 2025 goals to support the company’s mission to transform the lives of patients and bring forth a new era in medicine: tinyurl.com/3yepvz89 #CRISPR #GeneEditing

$NTLA announces its 2025 goals to support the company’s mission to transform the lives of patients and bring forth a new era in medicine: tinyurl.com/3yepvz89 #CRISPR #GeneEditing

Impressive data update from our nex-z program (aka NTLA-2001 for #ATTR)! Congrats to all! Teamwork makes the dream work. #OneIntellia

#ATTR News: $NTLA announces positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) in patients with #ATTR amyloidosis with cardiomyopathy. Full details here: tinyurl.com/33buvne7. Join us at 12 p.m. ET for a webcast discussing the data, as well as an update from the ongoing Phase 1 polyneuropathy cohort. event.choruscall.com/mediaframe/web… #CRISPR #GeneEditing

#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the @ACAAI Scientific Meeting in Boston. Details here: ir.intelliatx.com/news-releases/…

NEWS: $NTLA receives authorization by the @MHRAgovuk to initiate a Phase 1/2 of NTLA-3001 for the treatment of #alpha1 antitrypsin deficiency-associated lung disease. This is Intellia's first wholly owned in vivo gene insertion program. ir.intelliatx.com/news-releases/… #CRISPR #AATD

Company News: @intelliatx's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA Full video: biotechtv.com/post/intellia-…

Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at @EAACI_HQ 2024 Congress. Full details here: ir.intelliatx.com/news-releases/… #HAE #CRISPR #geneediting

#ATTR News: Intellia doses the first patient in its Phase 3 MAGNITUDE study of NTLA-2001 for the potential treatment of #transthyretinamyloidosis with cardiomyopathy: ir.intelliatx.com/news-releases/… #GeneEditing #CRISPR